Last updated: September 7, 2026
Collagenase clostridium histolyticum is a specialized biologic marketed primarily as Xiaflex in the United States. Endo Pharmaceuticals commercializes Xiaflex for Dupuytren's contracture and Peyronie's disease. The product generated several hundred million dollars in annual sales before facing maturing exclusivity, procedural competition, payer controls, and the withdrawal of the cellulite product Qwo. The asset remains commercially relevant because no approved biosimilar or generic competitor has established a market presence, but its growth profile is constrained by its narrow indications and dependence on physician-administered procedures.
What products contain collagenase clostridium histolyticum?
The principal products are Xiaflex and Qwo. Both contain collagenase clostridium histolyticum, but they have different formulations, indications, dosing protocols, and regulatory histories.
| Product |
Active ingredient |
Indication |
Sponsor or commercial partner |
Current status |
| Xiaflex |
Collagenase clostridium histolyticum |
Dupuytren's contracture |
Endo Pharmaceuticals |
Commercialized in the U.S. |
| Xiaflex |
Collagenase clostridium histolyticum |
Peyronie's disease |
Endo Pharmaceuticals |
Commercialized in the U.S. |
| Xiapex |
Collagenase clostridium histolyticum |
Dupuytren's contracture and Peyronie's disease in certain markets |
International licensees |
Availability varies by jurisdiction |
| Qwo |
Collagenase clostridium histolyticum-aaes |
Moderate-to-severe buttock cellulite |
Endo Pharmaceuticals |
Commercial production and distribution discontinued |
The FDA approved Xiaflex in 2010 for Dupuytren's contracture and in 2013 for Peyronie's disease. Qwo received FDA approval in July 2020 but was withdrawn from the U.S. market after Endo announced that manufacturing and commercial challenges prevented continued production and distribution.[1][2]
How does collagenase clostridium histolyticum work?
Collagenase clostridium histolyticum is an injectable enzyme mixture that degrades collagen. Xiaflex contains two collagenase enzymes, AUX-I and AUX-II, produced by Clostridium histolyticum.
For Dupuytren's contracture, the physician injects the drug into a collagen-rich cord in the palm and later performs finger extension to disrupt the treated cord. For Peyronie's disease, the physician injects the drug into the penile plaque during a treatment course involving multiple injection cycles and modeling procedures.
The product's commercial model differs from a self-administered biologic:
- The drug is administered in a physician's office.
- Each treatment requires specialist training and procedural follow-up.
- Revenue depends on both drug reimbursement and physician willingness to perform the procedure.
- Product demand is sensitive to coding, coverage policy, patient selection, and availability of hand, urology, and dermatology specialists.
What is the financial trajectory of Xiaflex?
Xiaflex has been one of Endo's most important branded pharmaceutical assets. Product sales remained in the several-hundred-million-dollar range annually during the early 2020s, supporting Endo's branded portfolio while the company managed broader generic pricing pressure and restructuring.
Endo does not consistently disclose Xiaflex operating profit, contribution margin, or cash flow separately. Public filings identify net sales, commercial risks, litigation exposures, and product concentration, but they do not provide a complete product-level income statement.[3]
Revenue drivers
The main revenue drivers are:
- Peyronie's disease treatment volume, which generally carries a larger revenue opportunity per patient because treatment involves a multi-injection course.
- Adoption among urologists and hand surgeons.
- Insurance reimbursement and patient affordability.
- Expansion of treatment capacity at qualified physician practices.
- Continued availability of the product under Endo's commercial and manufacturing infrastructure.
Xiaflex's revenue ceiling is limited by the need for procedural administration. It does not have the broad primary-care prescriber base associated with chronic oral medicines or self-injected biologics.
Revenue pressure points
Revenue is exposed to several structural pressures:
- Surgical and minimally invasive alternatives.
- Physician preference for established procedures.
- Coverage restrictions and prior authorization.
- Treatment discontinuation after adverse events or inadequate response.
- A finite addressable population in the approved indications.
- Potential future competition from biosimilar or follow-on collagenase products.
Qwo did not materially diversify the commercial base. Its approval expanded the theoretical market into aesthetic medicine, but clinical and manufacturing issues prevented the product from developing into a durable revenue stream. Endo discontinued Qwo production and distribution in 2022.[2]
When does Xiaflex lose regulatory exclusivity?
Xiaflex received FDA approval as a biologic license application product. The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity for qualifying biologics. Xiaflex's original U.S. approval occurred in 2010, placing the core reference-product exclusivity period at approximately 2022.
The 2013 approval for Peyronie's disease did not create a new 12-year exclusivity period. A supplemental indication generally does not restart the reference product's exclusivity clock.
| Milestone |
Date |
| FDA approval for Dupuytren's contracture |
2010 |
| FDA approval for Peyronie's disease |
2013 |
| FDA approval of Qwo |
2020 |
| Approximate end of 12-year reference-product exclusivity for Xiaflex |
2022 |
| Qwo commercial withdrawal process |
2022 |
Loss of regulatory exclusivity does not produce immediate competition. A biosimilar sponsor must complete development, submit a 351(k) application, obtain FDA approval, and establish commercial access. For a complex enzyme biologic administered through a procedure, these requirements create more practical barriers than the end of statutory exclusivity alone would suggest.
What patents protect collagenase clostridium histolyticum products?
Protection for Xiaflex is likely to involve several patent categories rather than a single composition patent:
- Collagenase enzyme compositions.
- Purification and manufacturing methods.
- Stabilized formulations.
- Lyophilized or reconstituted dosage forms.
- Injection protocols.
- Methods for treating Dupuytren's contracture.
- Methods for treating Peyronie's disease.
- Product-specific dosing and treatment cycles.
Because Xiaflex is approved under a biologics license application, its patent information is not presented in the same manner as a conventional small-molecule product's Orange Book listing. The FDA Purple Book identifies licensed biological products and reference-product information, but it does not function as a complete patent listing equivalent to the Orange Book.[4]
A complete freedom-to-operate analysis therefore requires review of U.S. Patent and Trademark Office records, assignment histories, continuation applications, terminal disclaimers, and claim scope. The relevant commercial question is whether any surviving claims cover the marketed collagenase composition, its formulation, or a commercially important treatment method.
What is the Orange Book status of Xiaflex?
Xiaflex is not a conventional Orange Book small-molecule product. It is a biologic licensed under the Public Health Service Act. The relevant regulatory framework is the Purple Book and the 351(k) biosimilar pathway.
This distinction affects competitive timing:
- An abbreviated new drug application is not the ordinary pathway for Xiaflex competition.
- A potential competitor would normally pursue a biosimilar application.
- Patent certification mechanics differ from the standard Paragraph IV process used for small-molecule drugs.
- A biosimilar applicant must address reference-product exclusivity and patent litigation under the biologics framework.
Are there Paragraph IV challenges to Xiaflex?
No major publicly established Paragraph IV generic challenge is associated with Xiaflex's biologic approval pathway. A conventional ANDA Paragraph IV strategy is not the normal route for a product licensed as a biologic.
A future competitor could pursue a 351(k) biosimilar application and engage in the patent-disclosure and litigation process under the Biologics Price Competition and Innovation Act. That process is often described as the "patent dance." The legal analysis would focus on patent validity, infringement, enforceability, and potential launch timing rather than on a standard Orange Book certification alone.[5]
How strong is the patent estate for Xiaflex?
The commercial strength of the Xiaflex patent estate is moderate rather than absolute.
Factors supporting protection
- The enzyme product is complex to manufacture and characterize.
- Product quality depends on biological production, purification, potency, and formulation.
- Treatment methods can create additional claim categories.
- Physician-administered use may support practical barriers even after patent expiry.
- Manufacturing know-how may be difficult to replicate from public patent disclosures.
Factors limiting protection
- The original product has been marketed for more than a decade.
- Reference-product exclusivity has ended.
- A biosimilar sponsor can develop a nonidentical process while matching the required analytical and clinical standards.
- Method-of-use patents may be vulnerable if claims are narrow or if prior art discloses similar treatment protocols.
- The product's commercial value is concentrated in a limited number of indications.
The strongest remaining protection would generally be a valid claim covering a commercially necessary composition, formulation, manufacturing step, or dosing regimen. A narrow method-of-use claim would be less effective against a competitor that designs around the claimed protocol.
What formulation and manufacturing barriers affect competition?
Collagenase clostridium histolyticum presents greater development complexity than many conventional biologics. A competitor must establish comparable:
- Enzyme identity and activity.
- Relative proportions of AUX-I and AUX-II collagenases.
- Purity and impurity profile.
- Potency assay performance.
- Stability during storage and reconstitution.
- Sterility and container-closure integrity.
- Consistency across manufacturing batches.
The product is supplied as a sterile lyophilized powder that requires reconstitution before injection. Manufacturing scale, cold-chain controls, analytical comparability, and physician-use logistics can delay a competing product even after regulatory exclusivity expires.
These barriers do not create permanent protection. They increase development cost and may reduce the number of credible entrants.
What generic or biosimilar launch risks exist?
The near-term risk of a conventional generic launch is low because Xiaflex is a biologic. The medium-term risk is a biosimilar or interchangeable biological product, although the practical market impact would depend on substitution rules, physician confidence, payer contracting, and treatment economics.
| Competitive pathway |
Likelihood |
Expected impact |
| Conventional ANDA generic |
Low |
Not the ordinary regulatory route |
| 351(k) biosimilar |
Medium-term possibility |
Could pressure price and formulary access |
| Physician substitution with surgery |
High |
Can limit procedure volume |
| Competing injection or enzyme therapy |
Low to medium |
Depends on clinical development |
| Off-label alternatives |
Existing |
Creates treatment-level competition |
Automatic substitution may be less important than with self-administered biologics. Because Xiaflex is administered by a physician during a procedural visit, the treating specialist may influence product selection more directly than a retail pharmacist.
Which companies are challenging the collagenase market?
The most important competitors are not necessarily direct enzyme competitors. Xiaflex competes with:
- Needle aponeurotomy for Dupuytren's contracture.
- Surgical fasciectomy for Dupuytren's contracture.
- Penile traction devices and surgery for Peyronie's disease.
- Off-label intralesional injections for Peyronie's disease.
- Observation and conservative management in selected patients.
No approved U.S. biosimilar to Xiaflex had established meaningful commercial penetration through the latest publicly available regulatory information. The competitive field therefore remains procedure-led rather than molecule-led.
What licensing deals affect collagenase clostridium histolyticum?
Auxilium Pharmaceuticals developed and commercialized Xiaflex before Endo acquired Auxilium in 2015. The acquisition transferred the product and associated commercial infrastructure to Endo.[6]
International rights have varied by jurisdiction. The product has been marketed as Xiapex in certain non-U.S. markets, with local regulatory and commercial arrangements. European availability has been affected by commercialization decisions and market-specific status. International sales are therefore less predictable than U.S. Xiaflex revenue.
What litigation and settlement issues affect Xiaflex?
The principal legal risks are likely to arise from:
- Patent disputes involving collagenase compositions or formulations.
- Biosimilar patent litigation under the BPCIA.
- Product liability claims linked to tendon rupture, bleeding, swelling, or other injection-related events.
- Promotional and reimbursement compliance.
- Manufacturing and supply obligations.
The FDA label warns of serious adverse events, including tendon rupture, ligament damage, and injection-site complications in relevant treatment settings.[1] These risks can affect physician adoption, payer policy, informed-consent procedures, and litigation reserves.
No major publicly established biosimilar settlement controlling U.S. Xiaflex launch timing had become a central market event through the latest available public disclosures.
How does Xiaflex compare with competing treatment options?
| Attribute |
Xiaflex |
Needle aponeurotomy |
Surgery |
Peyronie's traction or surgery |
| Drug component |
Enzyme biologic |
None |
None |
Device or surgery |
| Administration |
Office injection and manipulation |
Office procedure |
Operating-room procedure |
Home device or surgery |
| Revenue model |
Product plus procedure |
Procedure fee |
Surgical reimbursement |
Device or surgical reimbursement |
| Main commercial barrier |
Reimbursement and training |
Physician skill |
Surgical capacity |
Patient adherence or invasiveness |
| Biosimilar exposure |
Possible |
None |
None |
None |
| Market expansion potential |
Limited by indications |
Broad within Dupuytren's care |
Broad but invasive |
Condition-specific |
What is the outlook for collagenase clostridium histolyticum?
Xiaflex is likely to remain a valuable niche biologic rather than a high-growth platform product. The U.S. business has durable clinical demand, established physician familiarity, and no immediate generic substitute. Its growth is constrained by market maturity, competing procedures, payer restrictions, and the absence of a successful aesthetic-market expansion after Qwo's withdrawal.
The most material future variables are:
- Whether a biosimilar sponsor enters the U.S. market.
- Whether Endo sustains pricing and reimbursement.
- Whether new formulations or delivery approaches extend commercial life.
- Whether physician adoption expands beyond current specialist networks.
- Whether patent litigation delays or accelerates biosimilar entry.
- Whether manufacturing issues affect supply reliability.
Key Takeaways
- Xiaflex is the principal U.S. collagenase clostridium histolyticum product.
- Endo acquired the asset through its 2015 acquisition of Auxilium.
- FDA approvals cover Dupuytren's contracture and Peyronie's disease.
- The product's 12-year biologic reference exclusivity period began in 2010 and reached its approximate endpoint in 2022.
- Xiaflex is governed by the biologics and Purple Book framework rather than the standard small-molecule Orange Book model.
- No conventional ANDA generic challenge is the expected competitive pathway.
- A future 351(k) biosimilar could create price and formulary pressure, but manufacturing complexity raises entry barriers.
- Qwo's 2020 cellulite approval did not produce a durable second commercial franchise and was withdrawn from the market in 2022.
- Revenue remains concentrated in a mature, procedure-based U.S. market.
- The strongest competitive threats are existing procedures and payer controls, followed by potential biosimilar entry.
FAQs
Is collagenase clostridium histolyticum a biologic or a small-molecule drug?
It is a biologic enzyme product. Xiaflex is licensed through a biologics license application and is subject to the FDA's biologics framework.
Can Xiaflex be substituted automatically by a generic?
A conventional generic substitution is not the expected pathway. Any competing product would more likely be developed as a biosimilar under section 351(k), with interchangeability and state substitution rules determining the practical effect.
Why was Qwo discontinued?
Endo discontinued Qwo after manufacturing and commercial challenges prevented continued production and distribution. The withdrawal removed the cellulite indication from the collagenase commercial portfolio.
Does Peyronie's disease create a new Xiaflex patent term?
The 2013 Peyronie's disease approval did not restart the original biologic reference-product exclusivity period. Any separate patent protection would depend on the scope and validity of indication, method, formulation, or manufacturing claims.
What is the largest financial risk to Xiaflex revenue?
The largest risks are procedure-level competition, reimbursement restrictions, and eventual biosimilar entry. A biosimilar could affect net price, but surgery and alternative procedures can reduce demand even without molecule-level competition.
References
- U.S. Food and Drug Administration. (2024). Xiaflex (collagenase clostridium histolyticum) prescribing information. https://www.accessdata.fda.gov
- Endo International plc. (2022). Endo announces discontinuation of Qwo production and distribution. https://www.endo.com
- Endo International plc. (2023). Annual report on Form 10-K for the year ended December 31, 2023. https://www.sec.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. https://www.fda.gov/drugs/biosimilars
- Endo International plc. (2015). Endo completes acquisition of Auxilium Pharmaceuticals. https://www.endo.com
